title: Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience.
abstract: BACKGROUND
  Solitary Fibrous Tumor is a rare type of soft tissue tumor of intermediate malignant potential which may recur or metastasize in 15-20% of cases. Data on the management of patients with advanced SFT is scarce: chemotherapy has been described as ineffective, while recent data suggests that anti-angiogenic therapies may be more efficient.
  
  
  METHODS
  We conducted a retrospective study on patients treated for advanced SFT at a single institution: from January 1994 to December 2011, 30 patients were treated in the Centre Léon Bérard for an advanced SFT.
  
  
  RESULTS
  Twenty-three patients received cytotoxic chemotherapy as first-line therapy. Best responses were 2 (9%) partial responses, 13 (57%) stable diseases (SD) and 8 (35%) progressive diseases (PD). Median Progression Free Survival (PFS) was 5.2 (95% CI: 3.2-7.1) months and 9 patients were free of progression at 6 months. Ten patients received an anti-angiogenic treatment (sunitinib or pazopanib) as a 2nd, 3rd or 4th line. Best responses were 5 SD and 5 PD; median PFS was 5.1 months (95% CI 0.7-9.6). Four patients (36%) were progression-free for more than 6 months. Two patients receiving pazopanib were without progression at 6 and 8 months and two patients receiving sunitinib were free of progression at 30 months.
  
  
  CONCLUSIONS
  Response rate with standard chemotherapy was low and PFS appear similar between cytotoxic chemotherapy and anti-angiogenic agents.
authors.affiliation: Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec, 69008, Lyon, France.
authors.forename: Alice
authors.initials: A
authors.lastname: Levard
authors.forename: Olfa
authors.initials: O
authors.lastname: Derbel
authors.forename: Pierre
authors.initials: P
authors.lastname: Méeus
authors.forename: Dominique
authors.initials: D
authors.lastname: Ranchère
authors.forename: Isabelle
authors.initials: I
authors.lastname: Ray-Coquard
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
authors.forename: Philippe A
authors.initials: PA
authors.lastname: Cassier
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D054364:Solitary Fibrous Tumors / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents